Skip to main content

Retinoblastoma and ocular oncology: current advances and management

Guest Editors:
Bruno F. Fernandes: Argumento Institute, Canada
Vikas Khetan: Flaum Eye Institute, USA


BMC Ophthalmology called for submissions to our Collection on "Retinoblastoma and ocular oncology: current advances and management".

Retinoblastoma is a rare but devastating form of eye cancer primarily affecting children. Recent advances in ocular oncology, have led to significant improvements in the management and treatment of this disease. Chemotherapy, radiation therapy, and surgery can be used to effectively manage retinoblastoma, preserving vision, and preventing metastasis. Moreover, advances in genetic testing and molecular diagnostics have allowed for a better understanding of the molecular basis of retinoblastoma and provided more precise prognostic information, leading to personalized treatment strategies. Despite these advances, managing retinoblastoma remains challenging, particularly in cases where the cancer has spread beyond the eye.

This Collection aimed to collate original research articles regarding the current advances and management of retinoblastoma in the field of ocular oncology.

Meet the Guest Editors

Back to top

Bruno F. Fernandes: Argumento Institute, Canada

Dr Bruno F. Fernandes is an ophthalmologist with a postdoctoral fellowship in Ocular Pathology at McGill University and Ocular Oncology at the Princess Margaret Hospital, University of Toronto. After completing his training, Dr. Fernandes was appointed Assistant Professor at McGill University in the departments of Ophthalmology and Pathology, and Associated Director in the Henry C. Witelson Ocular Pathology Laboratory. Currently, he leads the Argumento Institute, which aims to establish collaborations on interesting research projects and promote research in developing countries.

Vikas Khetan: Flaum Eye Institute, USA

Vikas Khetan is a Professor at the Flaum Eye Institute in Rochester, New York. He is a trained retina surgeon with 2 international fellowships, as well as the Chief Editor for the book "Intraocular Tumors". Prof Khetan was awarded the P SivaReddy International award at AIOS 2018, as well as the SAO award at the SAARC meeting in 2018. He is the recipient of the APAO Achievement Award, and the former Vice President of the Asia Pacific Society of Ocular Oncology and Pathology. Prof Khetan is a member of the Macula Society, the GMC committee ARVO and the AP section of AMPC ARVO. He serves as an Editorial Board Member of BMC Ophthalmology.

About the collection

BMC Ophthalmology is calling for submissions to our Collection on "Retinoblastoma and ocular oncology: current advances and management".

Retinoblastoma is a rare but devastating form of eye cancer primarily affecting children. Recent advances in ocular oncology, have led to significant improvements in the management and treatment of this disease. Chemotherapy, radiation therapy, and surgery can be used to effectively manage retinoblastoma, preserving vision, and preventing metastasis. Moreover, advances in genetic testing and molecular diagnostics have allowed for a better understanding of the molecular basis of retinoblastoma and provided more precise prognostic information, leading to personalized treatment strategies. Despite these advances, managing retinoblastoma remains challenging, particularly in cases where the cancer has spread beyond the eye.

This Collection aims to collate original research articles regarding the current advances and management of retinoblastoma in the field of ocular oncology. Potential topics can include, but are not limited to, the following:

•    Genetic testing and counselling for retinoblastoma patients and their families
•    Biomarker discovery and validation for retinoblastoma diagnosis and treatment
•    The impact of early detection on the prognosis and outcome of retinoblastoma
•    Development of new treatments for retinoblastoma, such as targeted therapies, immunotherapies, or proton therapy
•    The role of chemotherapy in treating retinoblastoma and its long-term effects
•    Advancements in surgical techniques for retinoblastoma treatment, such as intra-arterial chemotherapy
•    The use of artificial intelligence and machine learning for diagnosis and treatment planning of retinoblastoma

Image credit: Paulista / stock.adobe.com

  1. Retinoblastoma (RB) is an intraocular malignant tumor detected in early childhood with variable global impact. Histopathological classification of the tumor in enucleated globes with RB is the key for the deci...

    Authors: Hind Manaa Alkatan, Alaa Almuzaini, Hala A. Helmi and Azza MY Maktabi
    Citation: BMC Ophthalmology 2024 24:309
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Retinoblastoma and ocular oncology" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Guest Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Guest Editors have competing interests is handled by another Editorial Board Member who has no competing interests.